文献速递关节外科手外科与足踝外科

双侧与单侧终末期踝关节炎的生活质量及双侧与单侧全踝关节置换术的结局

Quality of Life in Bilateral Vs. Unilateral End-Stage Ankle Arthritis and Outcomes of Bilateral Vs. Unilateral Total Ankle Replacement.
PubMed 文献 · J Bone Joint Surg Am · 2017-01-01

这项回顾性队列研究比较了双侧与单侧终末期踝关节炎患者的术前健康相关生活质量,并比较了分期双侧全踝关节置换术(TAR)与单侧TAR的中期结局。双侧组术前SF-36躯体成分评分低于单侧组,但两组术后SF-36躯体成分评分相似,金属部件翻修率和假体生存率无显著差异。

要点

  • 双侧终末期踝关节炎患者的术前SF-36躯体成分评分低于单侧患者,疾病负担更重。
  • 分期双侧TAR与单侧TAR术后SF-36躯体成分评分相似(p=0.70)。
  • 两组金属部件翻修率(6% vs 8%,p=0.52)和假体生存时间(p=0.60)无显著差异。

核心结论

  • 术前SF-36评分显示双侧终末期踝关节炎比单侧关节炎更使人衰弱。
  • 接受分期双侧TAR的患者尽管术前健康状况更差,其获益与接受单侧TAR的患者相当。
  • 两组金属部件翻修率和假体生存率相似。

研究设计与样本

  • 回顾性队列研究,从加拿大骨科足踝协会前瞻性踝关节重建数据库识别53例双侧终末期踝关节炎患者与106例单侧患者比较术前健康相关生活质量。
  • 比较37例分期双侧TAR患者与106例单侧TAR患者的中期结局(假体生存、健康相关生活质量、再手术和翻修率),所有患者随访至少2年。
  • 证据等级:治疗性III级。

主要发现

  • 术前单侧组创伤性关节炎患病率更高,双侧组原发性和继发性关节炎患病率更高(p < 0.001)。
  • 单侧组术前SF-36躯体成分总结(PCS)平均评分高于双侧组(p < 0.002)。
  • 双侧TAR组术后平均随访5.0 ± 2.0年,单侧TAR组4.0 ± 1.8年。
  • 单侧或分期双侧TAR患者术前至术后SF-36 PCS评分均改善(p < 0.001)。
  • 单侧TAR与双侧TAR患者术后SF-36 PCS评分相似(p = 0.70)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We performed a retrospective cohort study to compare preoperative health-related quality of life (HRQoL) between patients with bilateral and those with unilateral end-stage ankle arthritis. We also compared midterm outcomes in a subgroup of patients who had undergone staged bilateral total ankle replacement (TAR) with the outcomes in the group treated with unilateral TAR. METHODS: The HRQoL before surgical treatment was compared between 53 patients with bilateral end-stage ankle arthritis identified from the Canadian Orthopaedic Foot and Ankle Society Prospective Ankle Reconstruction Database and 106 patients with unilateral arthritis selected from the same database. Short Form-36 (SF-36) and American Academy of Orthopaedic Surgeons Foot and Ankle Module (AAOS-FAM) scores were used to assess preoperative HRQoL. Midterm outcomes (implant survival, HRQoL, and reoperation and revision rates) were compared between 37 patients who had undergone staged bilateral TAR and 106 patients treated with unilateral TAR; all patients were followed for at least 2 years. RESULTS: Preoperatively, patients with unilateral disease had a higher prevalence of posttraumatic arthritis, whereas patients with bilateral disease had a higher prevalence of primary and secondary arthritis (p < 0.001). The mean preoperative SF-36 physical component summary (PCS) score in the unilateral group was higher than that in the bilateral group (p < 0.002). The mean postoperative follow-up (and standard deviation) was 5.0 ± 2.0 years in the bilateral TAR group and 4.0 ± 1.8 years in the unilateral TAR group. The patients who underwent either unilateral or staged bilateral TAR demonstrated improved SF-36 PCS scores between the preoperative and postoperative evaluations (p < 0.001). The postoperative SF-36 PCS scores were similar between the patients with unilateral TAR and those with bilateral TAR (p = 0.70). Six ankles (6%) in the unilateral cohort and 6 ankles (8%) in the bilateral cohort required revision of the metal component (p = 0.52). The mean implant survival time was 10.9 years (95% confidence interval [CI] = 10.1 to 11.7 years) in the bilateral cohort and 9.2 years (95% CI = 8.5 to 9.8 years) in the unilateral cohort (p = 0.60). CONCLUSIONS: Preoperative SF-36 scores demonstrated that bilateral end-stage ankle arthritis is a more debilitating condition than unilateral arthritis. Patients who underwent staged bilateral TAR benefited as much as patients who underwent unilateral TAR, despite having a worse preoperative health status. Metal component revision rates and implant survival were similar between the 2 groups. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Desai SJ, Glazebrook M, Penner MJ, et al. Quality of Life in Bilateral Vs. Unilateral End-Stage Ankle Arthritis and Outcomes of Bilateral Vs. Unilateral Total Ankle Replacement. J Bone Joint Surg Am. 2017. PMID: 28099303. doi:10.2106/JBJS.16.00398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。